The DOI matches its Crossref record.
Defining clinically significant prostate cancer on the basis of pathological findings
Abstract
The definition of clinically significant prostate cancer is a dynamic process that was initiated many decades ago, when there was already evidence that a great proportion of patients with prostate cancer diagnosed at autopsy never had any clinical symptoms. Autopsy studies led to examinations of radical prostatectomy (RP) specimens and the establishment of the definition of significant cancer at RP: tumour volume of 0.5 cm 3, Gleason grade 6 [Grade Group (GrG) 1], and organ‐confined disease. RP studies were then used to develop prediction models for significant cancer by the use of needle biopsies. The first such model was used to delineate the first active surveillance (AS) criteria, known as the ‘Epstein’ criteria, in which patients with a cancer Gleason score of 3 + 3 = 6 (GrG1) involving fewer than two cores, and <50% of any given core, and a prostate‐specific antigen density of <0.15 ng/ml per cm 3 had a minimal risk of significant cancer at RP. These were adopted as components of the ‘very‐low‐risk category’ of the National Comprehensive Cancer Network guidelines, in which AS is supported as a management option. With the increase in the popularity of AS, much research has been carried out to better define significant/insignificant cancer, in order to be able to safely offer AS to a larger proportion of patients without the risk of undertreatment. Research has focused on allowing higher volume tumours, focal extraprostatic extension, and a limited amount of Gleason pattern 4, and the significance of different morphological patterns of Gleason 4. Other areas of research that will probably impact on the field but that are not covered in this review include the molecular classification of tumours and imaging techniques.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pantanowitz, L., Quiroga-Garza, G. M., Bien, L., Heled, R., Laifenfeld, D., Linhart, C., Sandbank, J., Albrecht Shach, A., Shalev, V., Vecsler, M., et al. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30159-x · Cited by 360
Raciti, P., Sue, J., Ceballos, R., Godrich, R., Kunz, J. D., Kapur, S., Reuter, V., Grady, L., Kanan, C., Klimstra, D. S., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0551-y · Cited by 186
Perincheri, S., Levi, A. W., Celli, R., Gershkovich, P., Rimm, D., Morrow, J. S., Rothrock, B., Raciti, P., Klimstra, D., & Sinard, J. (2021) · Modern Pathology · doi:10.1038/s41379-021-00794-x · Cited by 154
Metadata
- Authors
- Matoso, A., & Epstein, J. I.
- Venue
- Histopathology
- Publisher
- Wiley
- Published
- 2018-12-18
- Volume
- 74
- Issue
- 1
- Pages
- 135-145
- ISSN
- 0309-0167 (ISSN-L)
- 1365-2559
- OpenAlex
- W2905311859
- Cited by
- 198
- References
- 0
- FWCI
- 11.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Defining clinically significant prostate cancer on the basis of pathological findings. https://app.cochat.ai/papers/10.1111/his.13712
- The paper
- Matoso, A., & Epstein, J. I. (2019). Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology. https://doi.org/10.1111/his.13712
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.